# Ilika CEO on Stereax production, Goliath progress, and growing market demand

- Link: https://www.directorstalkinterviews.com/ilika-ceo-on-stereax-production-goliath-progress-and-growing-market-demand/4121228848
- Published: 2025-11-23T12:33:00+00:00
- Author: Amilia Stone

**[Ilika plc](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l) (
[LON:IKA](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)) **Chief
Executive Officer Graeme Purdycaught up with DirectorsTalk to discuss developments
in their Stereax and Goliath battery programmes, including production milestones,
customer engagement, and upcoming events.

**Q1: Graeme, in August, Ilika announced the successful completion of process qualification
for Stereax Manufacturing at Cirtec’s facility. How are the first production runs
going?**

**A1**: It’s been so satisfying actually to see the whole process running from beginning
to end, working together with Cirtec Medical, our scale-up partners, and we’ve seen
the wafers go all the way through, being processed into dyes, being stacked. So ,
actually, we’re very excited about the progress that’s been made that’s now starting
to bear fruit in terms of having product that we’ve got on test ready for release
to customers.

**Q2: How is customer demand for Stereax developing?**

**A2**: What we’ve also seen is that that initial pipeline of customers that we 
put together following our activities on the pilot line that we had set up here 
at our facility in the UK has further developed. We’ve been working hand in glove
with the Cirtec business development team and keeping all of those relationships
warm while they wait for further deliveries. We’re very happy at the prospects that
we’ve got there.

I think the other thing to say is that some of these areas that the Stereax battery
is designed to address are seeing significant growth and very strong demand in terms
of end applications coming to fruition. So, things like implanted sensors, so things
like blood pressure, etc., orthopaedic implants, neurostimulators, orthodontic devices
for aligners and for health monitoring, and then also some ophthalmological applications
as well. So, some really great sectors that we’re selling into.

**Q3: Will Cirtec and yourselves be promoting Stereax at any events that are coming
up?**

**A3**: Just as we sit here talking, there is an event going on in Silicon Valley
called MEDevice, and Cirtec are representing both their product portfolio and, of
course, Ilika’s as part of that. So, that’s actually ongoing today if you happen
to be in Silicon Valley.

In January, there’s another event called the NANS event or North American Neurostimulation
Society, and we will actually be together with Cirtec representing our offering 
at that, followed up in February by MD&M, which is an important conference and event
that we often go to.

**Q4: Now, back in May, Ilika announced customer validation of its 2Ah prototypes,
what you call Goliath P1 cells. It sounds now that you’re nearly ready to send out
your larger 10Ah cells. Is that right?**

**A4**: So, we’ve referred to these as a P1.5 prototypes. We’ve given guidance that
we want to release these by the end of the calendar year. We’ve got a series of 
batches of cells that have been on test, and the results are very encouraging. We
think that we’ve cleared the hurdle that we set ourselves, the bar, the performance
criteria for releasing those.

So, we can be proud of the progress that we’ve made, just in the space of 6/7 months
since we got feedback on the P1 cells. We anticipate releasing the initial batches
of those to our customers before the end of the year and into 2026.

**Q5: Are you making these batteries on your own equipment?**

**A5**: Yes, absolutely. That’s really one of the milestones that we’ve hit this
year, is that we’ve completed that 1.5 megawatt-hour pilot line that we said we 
wanted to build so that has allowed a massive increase in productivity.

That’s really important to get that reproducibility, because one of the challenges,
if you have a process where there’s a lot of manual intervention, is not only does
it take longer, but also you get variability because people do things slightly differently,
you know, one technician to another, one operator to another, and you end up with
having an unwanted degree of variability in your product.

So, by implementing this automation, we’re now getting much tighter data sets, and
the performance of the batteries is much closer to the absolute numbers that appear
on spec sheets.

**Q6: After the award of the grant funding you announced in July, you must be pleased
with the level of government support that you’ve been receiving for the Goliath 
programme?**

**A6**: Yes, absolutely. So, that was a great grant award that we’ve had. We’ve 
now completed the first quarter of execution of that programme and it’s great to
still be collaborating with the UK Battery Industrialisation Centre and have the
steering oversight of the University of Oxford to make sure that we’re using state-
of-the-art approaches and also Jaguar Land Rover. So, some great commercial interaction
as part of those discussions.

We expect actually our activities and that particular grant to accelerate in the
second half of the financial year that we’ve just started, and then beyond that 
with further grant awards that we’re currently applying for.

Share on:
